We recently compiled a list of the 12 Hot Stocks to Buy According to Analysts. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against the other hot stocks.

Learn more about whether Blueprint Medicines Corporation or Zai Lab Limited is a better investment based on AAII's A+ ...

Zai Lab (NASDAQ:ZLAB – Get Free Report) was upgraded by stock analysts at Cantor Fitzgerald to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports. Separately ...

Chinese regulators have accepted Zai Lab's (NASDAQ:ZLAB) market application for the drug KarXT, also known as xanomeline and trospium chloride, for the treatment of schizophrenia in adults.

NDAQ:ZLAB) Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell ...

The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

Zai Lab (NASDAQ:ZLAB) announced Wednesday it would seek marketing approval for its cervical cancer therapy Tivdak (tisotumab vedotin) in China after patients who took part in the Chinese segment ...

Zai Lab (ZLAB) announced topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demonstrating a clinically meaningful improvement in overall survival with TIVDAK ...

In a report released on January 13, David Li from Bank of America Securities maintained a Buy rating on Zai Lab (ZLAB – Research Report), with a price target of $29.00. The company’s shares ...

SHANGHAI & CAMBRIDGE, Mass., January 28, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2024 financial results and provide ...

View Zai Lab Limited (ZLAB) current and estimated P/E ratio data provided by Seeking Alpha.